InvestorsHub Logo
Post# of 252301
Next 10
Followers 6
Posts 703
Boards Moderated 0
Alias Born 09/23/2006

Re: DewDiligence post# 240123

Monday, 10/25/2021 10:16:28 AM

Monday, October 25, 2021 10:16:28 AM

Post# of 252301
EYEN" from the CEO-"Fortunately, we had taken actions throughout the development of MydCombi to minimize the impact of a potential reclassification by the FDA. We are preparing additional documentation requested by the FDA and look forward to resubmitting our NDA in early 2022 for the FDA’s review."

I have no idea(s) about what extra data they collected on the drug delivery device (their proprietary Optejet), but it is clear that the re-submission timeline now places a new PDUFA date in late 2022 at best. By that time, they should also have in the submission pipeline their pilocarpine studies.

This is now a "wait and see" investment, for sure. I don't have the time to research the specifics of the Genus Medical Technologies, LLC v. FDA, but will be looking at this case as time permits.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.